We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effect of Ketone Esters in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04477161
Recruitment Status : Completed
First Posted : July 20, 2020
Last Update Posted : January 4, 2022
Information provided by (Responsible Party):
University of Florida

Brief Summary:
Ketones esters have shown to improve mitochondrial function and are currently use to enhanced functional performance. As Mitochondrial dysfunction is one of the proposed mechanism of neuronal injury in Parkinson's disease, the study aims to assess the tolerability,side effects and effect of oral ketone esters in Patients with Parkinson's disease.

Condition or disease Intervention/treatment Phase
Parkinson Disease Ketosis Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink Other: Stool Sample Not Applicable

Detailed Description:

Parkinson's Disease (PD) is a debilitating progressive neurodegenerative disorder, second in frequency only to Alzheimer's disease, affecting around 10 million people worldwide. PD is characterized by loss of dopaminergic cells in substantia nigra and the accumulation of Lewy bodies. There is no disease modifying treatment or cure for the disease and management strategies focus on symptomatic treatment. One of the proposed mechanisms for the dopaminergic neurons degeneration in sporadic Parkinson's disease cases is related to compromise cellular bioenergetics, resulting in excessive production of reactive oxygen species (ROS) that leads to oxidative stress. Numerous studies have identified mitochondrial dysfunction as the central pathological features of both genetic and sporadic PD. Mitochondrial dysfunction can also increase inflammation which is associated with PD and Lewy Body formation. Elevated plasma ketones have been shown to enhance energy reserves, ATP levels and the expression of many enzymes involved in multiple metabolic pathways in the mitochondria. This pilot study aims to assess the effect of an exogenous ketone supplement on functional performance in people with PD. Changes in inflammatory makers will also be assessed. Participants will ingest the exogenous ketone supplement four times per day for four weeks. Participants will undergo neurological, functional, and cognitive assessments prior to and after the four-week intervention. Dietitians will follow up with participants weekly for compliance and counseling. Diet will be assessed throughout the study using the automated self-administered 24-hour dietary recall. After the four week intervention, a two-week "washout" period will be observed before reassessing functional and cognitive performance again.

Additionally, the study would like to establish the extent to which the use of Ketone esters impact the gut microbiota. Gut microbita composition in PD has been associated with symptoms and treatment efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: pilot, prospective, single-arm, single-center study
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial.
Actual Study Start Date : September 5, 2019
Actual Primary Completion Date : November 5, 2020
Actual Study Completion Date : November 5, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ketone Intervention
Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink
Subjects will take one bottle four times daily for four weeks

Other: Stool Sample
Subjects will provide a stool sample at 2 timepoints.

Primary Outcome Measures :
  1. Changes in serum Ketones [ Time Frame: Baseline up to 4 months ]
    by measuring the beta-hydroxybutyrate/serum glucose levels in blood at baseline and four months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Physician-diagnosed Parkinson's Disease
  • 40-75 years of age
  • On stable dopaminergic therapy
  • Willing and able to complete the informed consent form in English
  • Willing to consume the study supplement four times each day during the 4-week intervention period
  • Willing to complete all dietary recalls over approximately 6 weeks
  • Willing to complete all daily and weekly questionnaires throughout the six weeks.

Exclusion Criteria:

  • Does not meet the above criteria
  • Atypical or secondary Parkinsonism
  • BMI >30
  • Rheumatological or other inflammatory conditions
  • Following of the ketogenic diet
  • History of ulcer disease
  • History of irritable bowel disorder or irritable bowel syndrome
  • Currently taking any medication that could affect stool formation.
  • Diagnosis of Diabetes mellitus Type 1 or Type 2
  • Currently smoking (including vaping) tobacco products.
  • Women who are lactating, know that they are pregnant, or are attempting to get pregnant.
  • Note: a pregnancy test will be administered prior to initiating consumption of the study supplement. Women who are pregnant will be withdrawn from the study at that time.
  • Use of another investigational product within 3 months of the initial visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04477161

Layout table for location information
United States, Florida
Fixel Institute for Neurological Diseases
Gainesville, Florida, United States, 32608
Sponsors and Collaborators
University of Florida
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT04477161    
Other Study ID Numbers: Ketone in PD
IRB201901326 ( Other Identifier: UF IRB )
OCR24402 ( Other Identifier: UF OnCore )
First Posted: July 20, 2020    Key Record Dates
Last Update Posted: January 4, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Participant data will be shared with collaborators on project here at the University of Florida and only de-identified data will be released with IRB approval.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Florida:
parkinson disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Acid-Base Imbalance
Metabolic Diseases